GlaxoSmithKline posts loss as it integrates new businesses
Drug makers like GSK have been trying to focus on strengths amid competition from generic drug makers
British-based drug maker…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Novartis
Novartis’ two major trials shows significant efficacy of Cosentyx in ankylosing spondylitis…
The study enrolled anti-TNF naïve patients and patients who had previously failed anti-TNF therapy, with clinical benefits…
Regulatory submission for Sandoz’ proposed biosimilar pegfilgrastim accepted by FDA
Proposed biosimilar pegfilgrastim filing is the second of ten regulatory filings planned over the next three years
Sandoz, a…
Kenya launches ‘Novartis Access’
Agreements signed with Kenyan government and NGOs include programmes to distribute medicines, raise disease awareness and…
Novartis launches access programme for 15 medicines
Novartis Access to be launched first in Kenya, Ethiopia and Vietnam
Novartis has launched Novartis Access, a portfolio of 15…
Sandoz launches Zarxio, the first biosimilar in US
Sandoz One Source, a patient services centre, was also launched
Zarxio by Sandoz, a Novartis company, is now available in the US.…
Novartis in global partnership with Amgen
To develop and commercialise pioneering neuroscience treatments
Novartis has entered into a global collaboration with Amgen to…
Novartis with WHO to work together to eliminate leprosy, sign five year agreement
Novartis Foundation's new leprosy contact tracing programme launched in five countries
US FDA approves Novartis’ eltrombopag
The approval was based on two randomised, double-blinded, placebo-controlled trials enrolling paediatric patients with chronic ITP…
Novartis acquires all remaining rights to GSK’s Ofatumumab
To develop treatments for MS and other autoimmune indications